Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors

Current JAK2 inhibitors used for myeloproliferative neoplasms (MPN) treatment are not specific enough to selectively suppress aberrant JAK2 signalling and preserve physiological JAK2 signalling. We tested whether combining a JAK2 inhibitor with a series of serine threonine kinase inhibitors, targeti...

Descripción completa

Detalles Bibliográficos
Autores principales: Choong, Meng Ling, Pecquet, Christian, Pendharkar, Vishal, Diaconu, Carmen C, Yong, Jacklyn Wei Yan, Tai, Shi Jing, Wang, Si Fang, Defour, Jean-Philippe, Sangthongpitag, Kanda, Villeval, Jean-Luc, Vainchenker, William, Constantinescu, Stefan N, Lee, May Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117552/
https://www.ncbi.nlm.nih.gov/pubmed/24251790
http://dx.doi.org/10.1111/jcmm.12156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117552/
https://www.ncbi.nlm.nih.gov/pubmed/24251790
http://dx.doi.org/10.1111/jcmm.12156

Ejemplares similares